[HTML][HTML] Signaling pathways and therapeutic interventions in gastric cancer

ZN Lei, QX Teng, Q Tian, W Chen, Y Xie… - Signal transduction and …, 2022 - nature.com
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …

[HTML][HTML] The role and mechanism of claudins in cancer

DW Wang, WH Zhang, G Danil, K Yang, JK Hu - Frontiers in Oncology, 2022 - frontiersin.org
Claudins are a tetraspan membrane protein multigene family that plays a structural and
functional role in constructing tight junctions. Claudins perform crucial roles in maintaining …

[HTML][HTML] Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

Y Kubota, A Kawazoe, S Mishima, Y Nakamura… - ESMO open, 2023 - Elsevier
Background We conducted comprehensive clinical and molecular characterization of
claudin 18.2 expression (CLDN18. 2) in advanced gastric or gastroesophageal junction …

Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials

D Kyuno, A Takasawa, K Takasawa, Y Ono… - Tissue …, 2022 - Taylor & Francis
Claudins are major components of tight junctions that maintain cell polarity and intercellular
adhesion. The dynamics of claudins in cancer cells have attracted attention as a therapeutic …

Claudin 18.2 as a novel therapeutic target

I Nakayama, C Qi, Y Chen, Y Nakamura… - Nature Reviews …, 2024 - nature.com
Abstract Claudin 18.2, a tight-junction molecule predominantly found in the nonmalignant
gastric epithelium, becomes accessible on the tumour cell surface during malignant …

[HTML][HTML] Perioperative tailored treatments for gastric cancer: times are changing

D Lavacchi, S Fancelli, E Buttitta, G Vannini… - International Journal of …, 2023 - mdpi.com
Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no
defined molecularly based treatment strategy. Unfortunately, nearly half of patients …

[HTML][HTML] Gastric cancer: mechanisms, biomarkers, and therapeutic approaches

S Choi, S Park, H Kim, SY Kang, S Ahn, KM Kim - Biomedicines, 2022 - mdpi.com
Gastric cancer (GC) remains one of the most common deadly malignancies worldwide.
Recently, several targeted therapeutics for treating unresectable or metastatic GC have …

[HTML][HTML] Global ring study to investigate the comparability of total assay performance of commercial claudin 18 antibodies for evaluation in gastric cancer

B Jasani, P Taniere, HU Schildhaus, K Blighe… - Laboratory …, 2024 - Elsevier
Abstract Claudin 18.2 (CLDN18. 2), the dominant isoform of CLDN18 in gastric tissue, is a
highly specific tight junction protein of the gastric mucosa with variably retained expression …

[HTML][HTML] Gastric cancer: molecular mechanisms, novel targets, and immunotherapies: from bench to clinical therapeutics

T Baccili Cury Megid, AR Farooq, X Wang, E Elimova - Cancers, 2023 - mdpi.com
Simple Summary Gastric cancer (GC) is common but often diagnosed late. Recent advances
in chemotherapy, targeted therapy, and immunotherapy offer promising treatments …

Zolbetuximab for Claudin18. 2-positive gastric or gastroesophageal junction cancer

Y Kubota, K Shitara - Therapeutic Advances in Medical …, 2024 - journals.sagepub.com
Claudins (CLDNs) are a family of major membrane proteins that form components of tight
junctions. In normal tissues, CLDNs seal the intercellular space in the epithelial sheets to …